CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting, to be held in a virtual format from April 10 to 15 and May 17 to 21, 2021.
瑞士祖格和馬薩諸塞州坎布里奇，2021年3月10日(環球社)--CRISPR治療公司(納斯達克：CRSP)，一家專注於為嚴重疾病創造變革性的基於基因的藥物的生物製藥公司今天宣佈，它將在2021年4月10日至15日和5月17日至21日以虛擬形式舉行的美國癌症研究協會(AACR)年會上展示海報。
Title:CD70 knockout: A novel approach to augment CAR-T cell function
標題：CD70基因敲除：增強CAR-T細胞功能的新途徑
Session Title:Adoptive Cell Therapy
會話標題：採用細胞療法
Session Category:Immunology
會話類別：免疫學
Abstract Number: 1537, e-poster
抽象數：1537，電子海報
Date and Time:Saturday, April 10, 2021, 8:30 a.m. ET via the AACR website, www.aacr.org
日期和時間：2021年4月10日(星期六)上午8：30美國東部時間通過AACR網站www.aacr.org
About CRISPR Therapeutics
CRISPR治療公司簡介
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR治療公司是一家領先的基因編輯公司，專注於利用其專有的CRISPR/Cas9平台開發治療嚴重疾病的變革性基因藥物。CRISPR/CAS9是一項革命性的基因編輯技術，允許對基因組DNA進行精確的定向改變。CRISPR治療公司已經建立了涵蓋廣泛疾病領域的治療方案組合，包括血紅蛋白病、腫瘤學、再生醫學和罕見疾病。為了加快和擴大其努力，CRISPR治療公司已經與包括拜耳在內的領先公司建立了戰略合作關係，Vertex製藥公司CRISPR治療公司總部設在瑞士祖格，在美國設有全資子公司CRISPR治療公司，研發業務設在馬薩諸塞州劍橋，在舊金山、加利福尼亞州和英國倫敦設有業務辦事處。欲獲知更多信息，請訪問www.crisprtx.com。
CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.
CRISPR Treateutics®文字標記和設計標識是CRISPR Treateutics AG的商標和註冊商標。所有其他商標和註冊商標均為其各自所有者的財產。
Investor Contact:
投資者聯繫方式：
Susan Kim
蘇珊·金
+1-617-307-7503
+1-617-307-7503
susan.kim@crisprtx.com
郵箱：susan.kim@crisprtx.com
Media Contact:
媒體聯繫人：
Rachel Eides
瑞秋·艾德斯
WCG on behalf of CRISPR
WCG代表CRISPR
+1-617-337-4167
+1-617-337-4167
reides@wcgworld.com
郵箱：reides@wcgworld.com
譯文內容由第三人軟體翻譯。